Oana A Zeleznik1, Clary B Clish2, Peter Kraft3, Julian Avila-Pacheco2, A Heather Eliassen2,3, Shelley S Tworoger3,4. 1. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 2. Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, MA. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA. 4. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL.
Abstract
BACKGROUND: Experimental evidence supports a role of lipid dysregulation in ovarian cancer progression. We estimated associations with ovarian cancer risk for circulating levels of four lipid groups, previously hypothesized to be associated with ovarian cancer, measured 3-23 years before diagnosis. METHODS: Analyses were conducted among cases (N = 252) and matched controls (N = 252) from the Nurses' Health Studies. We used logistic regression adjusting for risk factors to investigate associations of lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), ceramides (CERs), and sphingomyelins (SMs) with ovarian cancer risk overall and by histotype. A modified Bonferroni approach (0.05/4 = 0.0125, four lipid groups) and the permutation-based Westfall and Young approach were used to account for testing multiple correlated hypotheses. Odds ratios (ORs; 10th-90th percentile), and 95% confidence intervals of ovarian cancer risk were estimated. All statistical tests were two-sided. RESULTS: SM sum was statistically significantly associated with ovarian cancer risk (OR = 1.97, 95% CI = 1.16 to 3.32; P = .01/permutation-adjusted P = .20). C16:0 SM, C18:0 SM, and C16:0 CERs were suggestively associated with risk (OR = 1.95-2.10; P = .004-.01; permutation-adjusted P = .08-.21). SM sum, C16:0 SM, and C16:0 CER had stronger odds ratios among postmenopausal women (OR = 2.16-3.22). Odds ratios were similar for serous/poorly differentiated and endometrioid/clear cell tumors, although C18:1 LPC and LPC to PC ratio were suggestively inversely associated, whereas C18:0 SM was suggestively positively associated with risk of endometrioid/clear cell tumors. No individual metabolites were associated with risk when using the permutation-based approach. CONCLUSIONS: Elevated levels of circulating SMs 3-23 years before diagnosis were associated with increased risk of ovarian cancer, regardless of histotype, with stronger associations among postmenopausal women. Further studies are required to validate and understand the role of lipid dysregulation in ovarian carcinogenesis.
BACKGROUND: Experimental evidence supports a role of lipid dysregulation in ovarian cancer progression. We estimated associations with ovarian cancer risk for circulating levels of four lipid groups, previously hypothesized to be associated with ovarian cancer, measured 3-23 years before diagnosis. METHODS: Analyses were conducted among cases (N = 252) and matched controls (N = 252) from the Nurses' Health Studies. We used logistic regression adjusting for risk factors to investigate associations of lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), ceramides (CERs), and sphingomyelins (SMs) with ovarian cancer risk overall and by histotype. A modified Bonferroni approach (0.05/4 = 0.0125, four lipid groups) and the permutation-based Westfall and Young approach were used to account for testing multiple correlated hypotheses. Odds ratios (ORs; 10th-90th percentile), and 95% confidence intervals of ovarian cancer risk were estimated. All statistical tests were two-sided. RESULTS:SM sum was statistically significantly associated with ovarian cancer risk (OR = 1.97, 95% CI = 1.16 to 3.32; P = .01/permutation-adjusted P = .20). C16:0 SM, C18:0 SM, and C16:0 CERs were suggestively associated with risk (OR = 1.95-2.10; P = .004-.01; permutation-adjusted P = .08-.21). SM sum, C16:0 SM, and C16:0 CER had stronger odds ratios among postmenopausal women (OR = 2.16-3.22). Odds ratios were similar for serous/poorly differentiated and endometrioid/clear cell tumors, although C18:1 LPC and LPC to PC ratio were suggestively inversely associated, whereas C18:0 SM was suggestively positively associated with risk of endometrioid/clear cell tumors. No individual metabolites were associated with risk when using the permutation-based approach. CONCLUSIONS: Elevated levels of circulating SMs 3-23 years before diagnosis were associated with increased risk of ovarian cancer, regardless of histotype, with stronger associations among postmenopausal women. Further studies are required to validate and understand the role of lipid dysregulation in ovarian carcinogenesis.
Authors: Qingchun Cai; Zhenwen Zhao; Caryl Antalis; Libo Yan; Giuseppe Del Priore; Ali Hassan Hamed; Frederick B Stehman; Jeanne M Schilder; Yan Xu Journal: FASEB J Date: 2012-07-05 Impact factor: 5.191
Authors: Mary K Townsend; Clary B Clish; Peter Kraft; Chen Wu; Amanda L Souza; Amy A Deik; Shelley S Tworoger; Brian M Wolpin Journal: Clin Chem Date: 2013-07-29 Impact factor: 8.327
Authors: Lian Shan; Y Ann Chen; Lorelei Davis; Gang Han; Weiwei Zhu; Ashley D Molina; Hector Arango; James P LaPolla; Mitchell S Hoffman; Thomas Sellers; Tyler Kirby; Santo V Nicosia; Rebecca Sutphen Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240
Authors: Elena Ioana Braicu; Silvia Darb-Esfahani; Wolfgang D Schmitt; Kaisa M Koistinen; Laura Heiskanen; Päivi Pöhö; Jan Budczies; Marc Kuhberg; Manfred Dietel; Christian Frezza; Carsten Denkert; Jalid Sehouli; Mika Hilvo Journal: Oncotarget Date: 2017-10-26
Authors: Marie Breeur; Pietro Ferrari; Laure Dossus; Mazda Jenab; Mattias Johansson; Sabina Rinaldi; Ruth C Travis; Mathilde His; Tim J Key; Julie A Schmidt; Kim Overvad; Anne Tjønneland; Cecilie Kyrø; Joseph A Rothwell; Nasser Laouali; Gianluca Severi; Rudolf Kaaks; Verena Katzke; Matthias B Schulze; Fabian Eichelmann; Domenico Palli; Sara Grioni; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Bas Bueno-de-Mesquita; Karina Standahl Olsen; Torkjel Manning Sandanger; Therese Haugdahl Nøst; J Ramón Quirós; Catalina Bonet; Miguel Rodríguez Barranco; María-Dolores Chirlaque; Eva Ardanaz; Malte Sandsveden; Jonas Manjer; Linda Vidman; Matilda Rentoft; David Muller; Kostas Tsilidis; Alicia K Heath; Hector Keun; Jerzy Adamski; Pekka Keski-Rahkonen; Augustin Scalbert; Marc J Gunter; Vivian Viallon Journal: BMC Med Date: 2022-10-19 Impact factor: 11.150
Authors: Matthew F Buas; Charles W Drescher; Nicole Urban; Christopher I Li; Lisa Bettcher; Nitai C Hait; Kirsten B Moysich; Kunle Odunsi; Daniel Raftery; Li Yan Journal: Sci Rep Date: 2021-09-13 Impact factor: 4.996
Authors: Oana A Zeleznik; Clemens Wittenbecher; Amy Deik; Sarah Jeanfavre; Julian Avila-Pacheco; Bernard Rosner; Kathryn M Rexrode; Clary B Clish; Frank B Hu; A Heather Eliassen Journal: Metabolites Date: 2022-04-20
Authors: Minoo Bagheri; Walter Willett; Mary K Townsend; Peter Kraft; Kerry L Ivey; Eric B Rimm; Kathryn Marie Wilson; Karen H Costenbader; Elizabeth W Karlson; Elizabeth M Poole; Oana A Zeleznik; A Heather Eliassen Journal: Am J Clin Nutr Date: 2020-12-10 Impact factor: 7.045
Authors: Jose Adriá-Cebrián; Sandra Guaita-Esteruelas; Eric W-F Lam; Marta Rodríguez-Balada; Jordi Capellades; Josefa Girona; Ana Maria Jimenez-Santamaria; Oscar Yanes; Luís Masana; Josep Gumà Journal: Cancers (Basel) Date: 2021-11-23 Impact factor: 6.639